936499
3-Pyridinecarboxylic acid, 6-[4-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]-1-piperazinyl]-
≥95%
동의어(들):
6-[4-[2-(2,6-Dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]-1-piperazinyl]-3-pyridinecarboxylic acid
로그인조직 및 계약 가격 보기
모든 사진(1)
크기 선택
보기 변경
50 MG
₩344,694
About This Item
실험식(Hill 표기법):
C23H21N5O6
CAS Number:
Molecular Weight:
463.44
UNSPSC 코드:
12352106
NACRES:
NA.22
추천 제품
Quality Level
분석
≥95%
양식
powder or crystals
색상
light yellow to dark yellow
저장 온도
2-8°C
SMILES string
O=C(O)C1=CN=C(C=C1)N2CCN(C3=CC=C4C(=O)N(C(=O)C4=C3)C5C(=O)NC(=O)CC5)CC2
InChI
1S/C23H21N5O6/c29-19-6-4-17(20(30)25-19)28-21(31)15-3-2-14(11-16(15)22(28)32)26-7-9-27(10-8-26)18-5-1-13(12-24-18)23(33)34/h1-3,5,11-12,17H,4,6-10H2,(H,33,34)(H,25,29,30)
InChI key
MZYKMQYHJGPMEI-UHFFFAOYSA-N
애플리케이션
This is a functionalized von-Hippel-Lindau (VHL) ligand with a terminal hydroxyl group. Allows rapid conjugation with many linkers containing active leaving groups. A basic building block for development of a protein degrader library.
Technology Spotlight:
Degrader Building Blocks for Targeted Protein Degradation
Protein Degrader Building Blocks
Technology Spotlight:
Degrader Building Blocks for Targeted Protein Degradation
Protein Degrader Building Blocks
기타 정보
- Targeted Protein Degradation by Small Molecules
- Destruction of DNA-Binding Proteins by Programmable Oligonucleotide PROTAC (O′PROTAC): Effective Targeting of LEF1 and ERG
- Small-Molecule PROTACS: New Approaches to Protein Degradation
- Targeted Protein Degradation: from Chemical Biology to Drug Discovery
- Impact of linker length on the activity of PROTACs
법적 정보
PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
가장 최신 버전 중 하나를 선택하세요:
시험 성적서(COA)
Lot/Batch Number
Jingwei Shao et al.
Advanced science (Weinheim, Baden-Wurttemberg, Germany), 8(20), e2102555-e2102555 (2021-08-17)
DNA-binding proteins, including transcription factors (TFs), play essential roles in various cellular processes and pathogenesis of diseases, deeming to be potential therapeutic targets. However, these proteins are generally considered undruggable as they lack an enzymatic catalytic site or a ligand-binding
Daniel P Bondeson et al.
Annual review of pharmacology and toxicology, 57, 107-123 (2016-10-13)
Protein homeostasis networks are highly regulated systems responsible for maintaining the health and productivity of cells. Whereas therapeutics have been developed to disrupt protein homeostasis, more recently identified techniques have been used to repurpose homeostatic networks to effect degradation of
Kedra Cyrus et al.
Molecular bioSystems, 7(2), 359-364 (2010-10-06)
Conventional genetic approaches have provided a powerful tool in the study of proteins. However, these techniques often preclude selective manipulation of temporal and spatial protein functions, which is crucial for the investigation of dynamic cellular processes. To overcome these limitations
Momar Toure et al.
Angewandte Chemie (International ed. in English), 55(6), 1966-1973 (2016-01-13)
The current inhibitor-based approach to therapeutics has inherent limitations owing to its occupancy-based model: 1) there is a need to maintain high systemic exposure to ensure sufficient in vivo inhibition, 2) high in vivo concentrations bring potential for off-target side effects, and 3) there is
Philipp M Cromm et al.
Cell chemical biology, 24(9), 1181-1190 (2017-06-27)
Traditional pharmaceutical drug discovery is almost exclusively focused on directly controlling protein activity to cure diseases. Modulators of protein activity, especially inhibitors, are developed and applied at high concentration to achieve maximal effects. Thereby, reduced bioavailability and off-target effects can
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.
